The estimated Net Worth of Capital Iii Llc Care Capita... is at least $17.8 Milion dollars as of 18 March 2015. Capital Capita owns over 1,206,700 units of Minerva Neurosciences Inc stock worth over $4,439,121 and over the last 10 years Capital sold NERV stock worth over $13,326,860.
Capital has made over 5 trades of the Minerva Neurosciences Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Capital sold 1,206,700 units of NERV stock worth $6,938,525 on 18 March 2015.
The largest trade Capital's ever made was selling 1,206,700 units of Minerva Neurosciences Inc stock on 18 March 2015 worth over $6,938,525. On average, Capital trades about 494,017 units every 42 days since 2014. As of 18 March 2015 Capital still owns at least 1,662,592 units of Minerva Neurosciences Inc stock.
You can see the complete history of Capital Capita stock trades at the bottom of the page.
Over the last 10 years, insiders at Minerva Neurosciences Inc have traded over $49,043,620 worth of Minerva Neurosciences Inc stock and bought 8,182,692 units worth $47,876,311 . The most active insiders traders include & Johnson Johnson & Johnson..., Venture Associates Iii Ltd ... a Capital Iii Llc Care Capita.... On average, Minerva Neurosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $556,476. The most recent stock trade was executed by Remy Luthringer on 28 April 2023, trading 27,394 units of NERV stock currently worth $105,193.
minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its
Minerva Neurosciences Inc executives and other stock owners filed with the SEC include: